Genolution

Genolution Fixed Asset Turnover

The Fixed Asset Turnover of Genolution (225220.KQ) as of Oct 22, 2026 is 0.12. In the previous year, Fixed Asset Turnover was 0.21 — a change of -40.29% (lower).

Fixed Asset Turnover

0.12

YoY

-40.29%

Last updated:

Fixed Asset Turnover of Genolution is 2024 0.12 . Fixed Asset Turnover of Genolution was 2023 0.21 . It decreases by -40.29% lower compared to the previous year.

The Genolution Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2017
3.00 KRW
Jan 1, 2018
0.71 KRW
Jan 1, 2019
0.51 KRW
Jan 1, 2020
5.30 KRW
Jan 1, 2021
3.41 KRW
Jan 1, 2022
0.89 KRW
Jan 1, 2023
0.21 KRW
Jan 1, 2024
0.12 KRW
The Genolution Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
0.12-40.29%
0.21-76.80%
0.89-73.73%
3.41-35.76%
5.30+938.62%
0.51-27.74%
0.71-76.42%
3.00-60.41%
7.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Fixed Asset Turnover of Genolution is 0.12 in 2024.

Fixed Asset Turnover of Genolution changed from 0.21 to 0.12, representing a -40.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Genolution since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genolution

All Key Metrics — Genolution